<?xml version="1.0" encoding="UTF-8"?>
<p>Agents which target the host are also potentially valuable treatment options. Interestingly, the agent camostat mesylate has been reported to block the cellular serine protease TMPRSS2, thereby inhibiting SARS-CoV-2 entry into host cells (
 <xref rid="B67" ref-type="bibr">67</xref>), and increases survival rates ~60% in an 
 <italic>in vivo</italic> SARS-CoV model (
 <xref rid="B199" ref-type="bibr">199</xref>). Camostat mesylate is widely used in Japan for chronic pancreatitis and postoperative reflux esophagitis (
 <xref rid="B200" ref-type="bibr">200</xref>, 
 <xref rid="B201" ref-type="bibr">201</xref>), and currently, a clinical trial in Denmark investigating the impact of this compound on COVID-19 is in its recruitment stage (
 <xref rid="B202" ref-type="bibr">202</xref>).
</p>
